Relay Therapeutics (RLAY) Current Assets (2019 - 2026)

Relay Therapeutics (RLAY) has reported Current Assets for 8 consecutive years, with $658.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets fell 10.98% year-over-year to $658.5 million; the TTM figure through Mar 2026 stood at $658.5 million (down 10.98% YoY), while the FY2025 annual figure was $578.3 million, down 28.54% from the prior year.
• Current Assets advanced to $658.5 million in Q1 2026 per RLAY's latest filing, from $578.3 million in the prior quarter.
• Across five years, Current Assets topped out at $1.1 billion in Q3 2022 and bottomed at $578.3 million in Q4 2025.
• Historically, Current Assets has averaged $809.0 million across 5 years, with a median of $809.2 million in 2024.
• Annual changes were most pronounced in 2022 — Current Assets surged 70.09% — and 2025, when it dropped 28.54%.
• Relay Therapeutics' Current Assets stood at $1.0 billion in 2022, then declined by 24.46% to $770.1 million in 2023, then rose by 5.08% to $809.2 million in 2024, then decreased by 28.54% to $578.3 million in 2025, then rose by 13.87% to $658.5 million in 2026.
• Business Quant data shows RLAY's Current Assets at $658.5 million in Q1 2026, $578.3 million in Q4 2025, and $624.0 million in Q3 2025.